ArticleAnnals of translational medicine2021
Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review.World journal of surgical oncology · 2025Pooled it
- Effect of intraoperative hyperthermic intrathoracic chemotherapy after pleurectomy decortication for treatment of malignant pleural mesothelioma: a comparative study.Updates in surgery · 2024Trial
- Hyperthermic intrathoracic chemotherapy in the management of pleural malignancies: current evidence, limitations, and future directions.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026Article
- Pleural Mesothelioma: Current Therapeutic Strategies and Future Directions.Current oncology reports · 2026Review
- Hyperthermic intrathoracic chemotherapy (HITHOC) in stage IVA thymomas: a narrative review.Mediastinum (Hong Kong, China) · 2025Review
- Review
- Update in the Treatment of Pleural Tumors: Robotic Surgery Combined with Hyperthermic Intrathoracic Chemotherapy.Cancers · 2024Review
- Impact of hyperthermic intrathoracic chemotherapy (HITHOC) during resection of pleural mesothelioma on patient survival.Journal of thoracic disease · 2023Article
- Hyperthermic intrapleural chemotherapy: an update.Journal of thoracic disease · 2023Review
- Article
- ERS International Congress 2021: highlights from the Thoracic Surgery and Lung Transplantation Assembly.ERJ open research · 2022Article
- Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma.Frontiers in oncology · 2022Review
- An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.Lung Cancer (Auckland, N.Z.) · 2022Review
- Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment.Journal of clinical medicine · 2021Review
- Present and future of hyperthermic intrathoracic chemotherapy (HITHOC) in thoracic surgical oncology.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.